Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-01-20 Major Shareholding Noti…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Securities Regulation of 29 June 2007 (“STA”) - Disclosure of Significant Shareholding
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Disclosure of Significant Shareholding' pursuant to the Securities Regulation of 29 June 2007 ('STA'). It details that a shareholding crossed the 5% threshold due to a purchase, resulting in a total holding of 5.01%. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2021-01-20 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document text is titled 'Financial calendar' and lists scheduled dates for future corporate events like 'Annual Report', 'Annual General Meeting', and 'Quarterly Report'. It is not the report itself, but rather an announcement detailing the schedule of future reports and meetings. Since there is no specific category for a 'Financial Calendar' announcement, and it is an announcement about future regulatory/corporate events, the most appropriate classification is the general fallback category for regulatory announcements, RNS, or potentially a Report Publication Announcement (RPA) if it were announcing the publication of a specific report. Given it is a forward-looking calendar, RNS (Regulatory Filings) is the best fit as a general announcement of corporate schedule information.
2021-01-20 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insider' concerning a Board member (Ketil Fjerdingen) buying shares. This directly corresponds to the definition of Director's Dealing (insider trades). Matching Definition: 2. Director's Dealing (Code: DIRS): Report of personal share transactions by company directors and executives (insider trades).
2021-01-15 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insider' concerning the CEO, Carlos de Sousa, buying shares. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Definition Match: Director's Dealing (Code: DIRS) - Report of personal share transactions by company directors and executives (insider trades).
2021-01-13 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insider' concerning the CEO, Carlos de Sousa, buying shares. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Category: Director's Dealing (Code: DIRS).
2021-01-12 English
Shareholder Notification: Ultimovacs ASA
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document provided is a 'Schedule A' detailing shareholdings in ULTIMOVACS ASA by various funds managed by FIL INVESTMENTS INTERNATIONAL. It explicitly lists the number of shares held, the total shares in issue, and calculates the resulting ownership percentage (4.91315%). This structure, focusing purely on the quantitative breakdown of ownership changes or current holdings by major entities, strongly aligns with the definition of a Major Shareholding Notification, which reports when ownership crosses specific thresholds. Therefore, the appropriate classification is MRQ (Major Shareholding Notification). The document is not a full report (10-K, IR), an earnings announcement (ER), or a management discussion (MDA), but a specific regulatory disclosure about ownership.
2020-12-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.